| 3.87 0.12 (3.2%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.4  |
1-year : | 9.32 |
| Resists | First : | 6.33 |
Second : | 7.98 |
| Pivot price | 4.68 |
|||
| Supports | First : | 3.68 |
Second : | 3.06 |
| MAs | MA(5) : | 3.98 |
MA(20) : | 4.78 |
| MA(100) : | 4.49 |
MA(250) : | 3.53 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 5.4 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 7.98 | Low : | 2.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IVA ] has closed above bottom band by 28.6%. Bollinger Bands are 147% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 22 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.99 - 4.01 | 4.01 - 4.03 |
| Low: | 3.64 - 3.66 | 3.66 - 3.68 |
| Close: | 3.84 - 3.87 | 3.87 - 3.9 |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Fri, 07 Nov 2025
Inventiva S.A. Announces General Meeting for November 27, 2025 - TipRanks
Thu, 06 Nov 2025
Wolfe Research Initiates Coverage on IVA with Outperform Rating - GuruFocus
Fri, 31 Oct 2025
Inventiva S.A. Prepares for November 2025 General Meeting with Key Proposals - The Globe and Mail
Mon, 20 Oct 2025
Inventiva Announces General Meeting to Discuss Strategic Resolutions - TipRanks
Fri, 10 Oct 2025
Piper Sandler reiterates Overweight rating on Inventiva stock ahead of key trial - Investing.com
Wed, 08 Oct 2025
Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA) - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 146 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 289 (K) |
| Shares Short P.Month | 66 (K) |
| EPS | -4.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | 0 % |
| Operating Margin | -991.9 % |
| Return on Assets (ttm) | -56.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 105.1 % |
| Gross Profit (p.s.) | 0.11 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -0.89 |
| PEG Ratio | 0 |
| Price to Book value | -64.5 |
| Price to Sales | 33.26 |
| Price to Cash Flow | -6.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|